Research programme: amyotrophic lateral sclerosis therapeutics - Eli Lilly/Project ALS
Latest Information Update: 28 Jul 2018
Price : *
At a glance
- Originator Eli Lilly; Project A.L.S.
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA
- 19 Nov 2013 Preclinical trials in Amyotrophic lateral sclerosis in USA (unspecified route)